(L.) Wettst. could be of interest in the control of symptoms of Parkinson’s disease, but clinical evidence of its efficacy is lacking. This clinical trial assessed the effects of an extract of on parameters that are related to Parkinson’s diseases. Twenty volunteers with Parkinson’s disease were recruited for a primary, interventional, controlled, parallel, double-blind clinical study. The volunteers were assigned to treatment with either a commercial extract (225 or 450 mg/day) or placebo. The Parkinson’s Disease Quality-of-Life (PDQL) questionnaire was applied, and motor activity was assessed before treatment and 30, 60, and 90 days after treatment with the extract or placebo. Characteristics such as age, body weight, and height were also collected. No differences in parkinsonian and systemic symptoms, emotional function, or social function were observed between. The delta percent (Δ%) showed time-dependent improvements in emotional function with treatment at the daily dose of 450 mg. A strong correlation was found between quality of life and motor outcomes at baseline and 30 days of treatment with , and a moderate correlation for 60 and 90 days of treatment with when compared with baseline time. A moderate correlation was found between motor outcomes and Hoehn and Yahr stages at baseline. Our results suggest that extract can improve emotional function in Parkinson’s disease patients, but further clinical trials are needed to confirm this possibility.
